Kevin Forbes, PhD Manager, In Vivo Research and Development , Horizon Discovery
YORBA LINDA, Calif. (PRWEB) May 14, 2018
The nuclear receptor pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of Phase I (Cytochrome P450s), Phase II drug metabolizing enzymes and drug transporter genes in response to stimulation from xenobiotics including prescription drugs. PXR and CAR knockout and humanized mouse models have proven useful in the study of drug metabolism.
The rat being bigger in size, is the preferred model system for studying drug metabolism and pharmacokinetics. Here, we report the creation and preliminary characterization of PXR and CAR knockout rats and PXR/CAR double knockout rats. Whereas, the expression of phase I and II enzymes and transporter genes were not upregulated by nuclear receptor-specific agonists in the knockout rats, confirming the disruption of respective nuclear receptor(s).
Through this webinar, which is sponsored by Horizon Discovery, participants will gain a better understanding of the benefit of rat models versus mouse models in functional studies on metabolic pathways. They will learn how rat hepatocytes can add value to drug development studies, as well as the utility of the PXR and CAR KO rat models.
Horizon Discovery manager of In Vivo R&D, Dr. Kevin Forbes, will be the speaker for this event. Forbes holds a doctorate from the University of Kentucky in plant physiology, after which he was a USDA post-doctoral fellow at the University of South Carolina. During his time in the in vivo group in St. Louis, MO USA, he has worked on developing and implementing gene editing technologies (CRISPR/Cas9 and ZFNs) for animal model generation. His primary focus has been rat ADME/TOX models for drug development. Specifically, nuclear receptor and P450 gene knock-outs and humanized rat models.
LabRoots will host the webinar May 22, 2018; beginning at 8 a.m. PDT. To learn more about this event, discover the continuing education credits offered, or to register for free, click here.
About Horizon Discovery Group plc
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon’s platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company’s own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”
About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.